BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

Inclusion Criteria:

1. Female patients aged from 18 to 45 years old;
2. Clinical/trichological evidence of telogen effluvium, assessed using the TelogenIndex. 3. Participants will be eligible if they have a rate strand of hair ≥ 20% ofthe total quantified by Thrichoscan measurement in the central-parietal region;
3. Complaint of hair loss for at least 3 months prior to screening;
4. Agreement to obey the procedures and requirements of the protocol and to attend theResearch Institution on the day (s) and time (s) determined for the evaluations;
5. Signature of the Informed Consent Form; SAW. Agreement to use an acceptablenon-hormonal contraceptive method throughout the period of treatment and up to 60 daysafter the end of the study;
6. Serum creatinine within the normal range;
7. Relationship between AST / ALT transaminases ≤ 2.5x the upper limit of normal

Exclusion Criteria:

1. Pregnancy or pregnancy risk;
2. Lactation;
3. Childbirth occurred in the last 12 months;
4. Patient who has undergone surgical procedures or has suffered trauma in the last 6months;
5. History of bleeding events in the last 6 months, SAW. Clinical evidence of femaleandrogenic alopecia or alopecia areata;
6. Patients with signs of menopause: menstrual irregularities or cycle failure, signs ofclimacteric;
7. Laboratory evidence of thyroid diseases (variation in TSH and / or free T4 valuesoutside normal limits);
8. Clinical evidence of ovarian or adrenal endocrine disorders (polycystic ovaries,hirsutism, menstrual irregularities);
9. History or presence of systemic autoimmune disease;
10. Start or end of hormone therapy within 6 months before randomization;
11. Deficiency diseases;
12. Introduction, change or interruption of a hormonal contraceptive method in the last 6months before randomization;
13. Introduction of a restrictive diet in the last 03 months before randomization;
14. Use of any continuous medication;
15. Diabetes, chronic consuming disease, malabsorptive syndrome or diseases of thegastrointestinal tract;
16. Infectious or chronic fever;
17. Psychiatric/psychological illnesses, such as depression, anxiety or obsessivedisorders;
18. Clinical and / or laboratory evidence of anemia or ferropenia; (Hb <12 g / dL andFerritin <40 g / L);
19. Hair treatment to control hair loss (including shampoo, conditioner, lotions);
20. Hair growth agent treatment within 3 months before randomization;
21. Concomitant use of drugs that cause hair loss;
22. Patient with a history of allergic reaction or hypersensitivity to any formulationingredients;
23. Other conditions considered by the evaluating physician to be reasonable fordisqualifying the participation in the study.